Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine A Randomized Clinical Trial

Source:

Lintzeris N, Dunlop AJ, Haber PS, et al. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial. JAMA Netw Open. 2021;4(5):e219041. doi:10.1001/jamanetworkopen.2021.9041

Key Points

Question  Are patient-reported outcomes, such as treatment satisfaction with medication, higher among patients treated with weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine?

Findings  In this open-label randomized clinical trial of 119 participants, the mean Treatment Satisfaction Questionnaire for Medication global score was significantly higher in the group receiving depot buprenorphine than in the group receiving sublingual buprenorphine at week 24.

Meaning  These findings suggest that treatment satisfaction and other patient-reported outcomes may serve as alternative end points to traditional markers of substance use when comparing different medications in addiction outcome studies.